

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001754937
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Allogene Therapeutics, Inc.
SEC File Number 001-38693
Address of Issuer 210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CALIFORNIA
94080
Phone (650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold MOORE ALISON

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	531854	3052841.96	145841620	06/12/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

			Whom Acquired	a Gift?			
Common Stock	06/12/2023	Exercise of employee stock options	Allogene Therapeutics, Inc.	<input type="checkbox"/>	437080	06/12/2023	Broker assisted cashless exercise
Common Stock	06/28/2019	Exercise of employee stock options	Allogene Therapeutics, Inc.	<input type="checkbox"/>	498	06/28/2019	Cash
Common Stock	03/13/2020	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.	<input type="checkbox"/>	5512	03/13/2020	Granted as part of issuer equity compensation plan
Common Stock	08/13/2020	Exercise of employee stock options	Allogene Therapeutics, Inc.	<input type="checkbox"/>	32451	08/13/2020	Cash
Common Stock	03/13/2021	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.	<input type="checkbox"/>	10799	03/13/2021	Granted as part of issuer equity compensation plan
Common Stock	03/13/2022	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.	<input type="checkbox"/>	23178	03/13/2022	Granted as part of issuer equity compensation plan
Common Stock	03/13/2023	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.	<input type="checkbox"/>	14829	03/13/2023	Granted as part of issuer equity compensation plan
Common Stock	03/15/2023	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	2000	03/15/2023	Cash
Common Stock	03/15/2022	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	1688	03/15/2022	Cash
Common Stock	09/15/2021	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	558	09/15/2021	Cash
Common Stock	03/15/2021	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	368	03/15/2021	Cash
Common Stock	09/15/2020	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	718	09/15/2020	Cash
Common Stock	03/13/2020	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	704	03/13/2020	Cash
Common Stock	09/13/2019	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	694	09/13/2019	Cash
Common Stock	03/15/2019	Employee stock purchase plan	Allogene Therapeutics, Inc.	<input type="checkbox"/>	507	03/15/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
----------------------------	--------------------------	--------------	---------------------------	----------------

Alison Moore
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO CA
94080

Common Stock

03/14/2023 8351

45989.75

144: Remarks and Signature

Remarks

Date of Notice

06/12/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Alison Moore

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)